In this post I want to share two charts from the weekend update of our Market Internals workbook, both of which confirm the continued deterioration in breadth as US Stocks make new lows.
Yesterday after the bell we sent out our Year End '18 ETF Risk Update to our Institutional Clients, covering 100+ of the most actionable and informative charts. To put this report together we examined over 500 inter-market and cross-asset relationships across weekly & daily time-frames to identify trend direction, momentum, risk-management levels, and prices targets.
In this premium post I want to highlight a few charts from each of our five sections: Factors, International, Domestic, Fixed-Income, and Thematic/Niche. If you like what you see and want the full report, you can fill out our Institutional Client Application or contact our Head of Institutional Sales, Jonathan Bloom, for access.
Two weeks ago we wrote that the weight of the evidence was suggesting the major indexes in India were getting ready to resume lower. While we were a few days early, most have resolved their consolidations lower. So the question now is, will they continue lower or will they be able to base and head higher? That's the question we're looking to answer in this post.
First let's start with the weakest area of the market, small-caps. Prices were consolidating for about a month in a super tight range, but are now resolving to the downside to continue their long-term downtrend.
Click on chart to enlarge view.
Mid-caps look equally as bad. Nothing in this chart suggests higher prices are ahead, quite the opposite actually.
There have been many whipsaws in the Commodities' market as of late, with few intermediate-term trends allowing us to trade them with well-defined risk. Every now and again the market provides us with a clear opportunity, this time it's in the form of a breakdown in Tumeric.
There's a saying among market participants that "all gaps need to be filled" or "all gaps are eventually filled", but as with most market generalizations, this saying shouldn't be taken at face value.
This post is going to discuss the four types of gaps and explain why this phrase is not something any market participant should take seriously.
We always hear the phrases "fading strength" or "selling into strength" from market participants, but what does that mean from a practical standpoint? How do you know what to sell? When do you sell?
In light of those questions, this week's "Chart of the Week" is going to help provide some context around the types of characteristics we look for when choosing stocks to fade.
This week's "Chart of the Week" answers the question about what characteristics determine the stocks we're fading strength in, so this premium post will outline the best setups I found during my review of the S&P 1500. If you haven't read the other post, click here to do so as it will provide more context around these trade ideas.
Over the last three weeks Sun Pharmaceuticals has been doing its best Deutsche Bank impression, losing roughly a third of its value and trading at levels not seen since March 2013.
As the largest component of the Nifty Pharmaceuticals Index this performance has been a major drag on the index, however, equally-weighted charts can offer us a much better read of the sector's health.
This post is a continuation of our "Free Chart of The Week", which focused on the use of an equally-weighted Pharmaceuticals Index to make the case that the sector is in better health than the cap-weighted index suggests.
In this post, we'll use that information to identify the stocks in this sector offering us the best reward/risk opportunities.
This past weekend we got new Monthly Charts, and overall the themes we discussed last month are very similar. With that being said, we'll use this post to discuss a few notable developments.
Crude Oil is down roughly 35% over the last two months as record bullish sentiment unwound and prices fell in what was essentially a straight line. There hasn't been any reason to bottom-fish this market, but today we received our first indication that a short-term bottom may be in.
During our members-only conference call and our trade management post we discussed why a more neutral approach is best as we identify whether equities are going to consolidate at higher levels or begin to roll over again. We also discussed the importance of taking some profits quickly in an environment that produces whipsaws in both directions.
Over the last two weeks we've seen a number of our long ideas failing and more of our short ideas working, suggesting that lower prices are likely ahead in the short-term and that we should continue to err on the short side of stocks. This post will outline some of the evidence we're seeing supporting this thesis, as well as adding a number of short ideas to our trade list from October and November.
